Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.

Abstract

These results show that high-dose outpatient radioimmunotherapy with an 125I-labeled internalizing antibody can be achieved without significant patient toxicity or radiation hazard.